News

ALK to become sole manufacturer and distributor of skin antigen test for penicillin allergy

– PRE-PEN® (benzylpenicilloyl polylysine injection USP) is the only FDA-approved diagnostic skin test for the evaluation of penicillin allergyi,ii –…

2 years ago

Former Biogen CEO Michel Vounatsos Joins Quris-AI Board

Yossi Ben Amram Appointed President as Bio-AI Innovator Continues to Expand Roster of Influential Experts Guiding Its Global Growth Yossi…

2 years ago

EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB)

EG427 Announces New Preclinical Results from Multiple Studies of EG110A in Neurogenic Detrusor Overactivity (NDO) and Overactive Bladder (OAB) In…

2 years ago

CytomX Therapeutics Outlines 2024 Company Priorities and Milestones

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data anticipated in the 2nd half of 2024 - - IND…

2 years ago

Viracta Therapeutics Provides Clinical Update and Outlook for 2024

Speed to market strategy for Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supported by complete enrollment…

2 years ago

Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference

Abstracts highlight the serious clinical burden of uncontrolled NASH and identify opportunities to improve patient careIn an analysis of patient…

2 years ago

Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases

Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and…

2 years ago

NewAmsterdam Pharma Announces 2024 Strategic Priorities

-- Positioned for three Phase 3 trial readouts over the next 18 months -- -- Topline data expected from Phase…

2 years ago

Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy

LSTA1, the Company’s lead investigational product, in combination with standard-of-care therapy, potentiated a complete response in a patient with metastatic…

2 years ago